ALLMedicine™ Gastrinoma Center
Research & Reviews 103 results
The American Journal of Case Reports; Musalli DI, Binafif YA et. al.
Apr 9th, 2022 - BACKGROUND Carcinoid tumors are well-differentiated tumors that develop from neuroendocrine cells. They are rare tumors and occur most commonly in the gastrointestinal tract, followed by the pulmonary system. They usually present with abdominal pa...
Journal of Neuroendocrinology; Ramage JK, Friend E et. al.
Feb 15th, 2022 - Pancreatic neuroendocrine tumours (panNET) are heterogeneous neoplasms usually characterised by slow growth and secretion of hormones, which often cause symptoms. The effect of these symptoms on quality of life (QoL) has not previously been examin...
Medicine Boeriu A, Dobru D et. al.
Jan 15th, 2022 - Gastric neuroendocrine neoplasms (g-NENs) represent a distinctive group of gastric tumors, stratified into different prognostic categories according to different histological characteristics, put forth in the 2018 World Health Organization classif...
The Journal of Clinical Endocrinology and Metabolism; Giusti F, Cioppi F et. al.
Dec 19th, 2021 - Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited endocrine cancer syndrome. Multiple gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) affect 30% to 80% of MEN1 patients, with the most common functioning GEP-NET being gastrin...
Dec 3rd, 2021 - Background A gastrinoma is a gastrin-secreting tumor usually found in the pancreas or duodenum. [1, 2] Duodenal wall tumors are frequently small and multiple. Sporadic tumors occurring in the pancreas tend to be solitary and have a greater maligna...
Drugs 9 results see all →
Clinicaltrials.gov 2 results
Jul 2nd, 2017 - Heretofore morbidity and mortality in Zollinger-Ellison syndrome were caused by severe ulcer disease. The advent of specific drugs to cure ulcer disease now extends life until metastases from the non-B-islet cell tumor or other events cause death....
Jul 2nd, 2017 - This protocol describes the use of histamine H2-receptor antagonists to control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. It details which patients will be considered for treatment with these agents, the pretreatment...
News 12 results
Sep 30th, 2021 - Updated clinical guidelines on the diagnosis and management of neuroendocrine and adrenal tumors were released in 2021 by the National Comprehensive Cancer Network (NCCN). The new version of the guidelines, published in the Journal of the National...
Apr 2nd, 2021 - Somatostatin analogs have historically been used for symptom control in patients with pancreatic neuroendocrine tumors (pNETs); however, these agents are now being considered for their antitumor properties. Functional patients with pNETs typically...
Dec 5th, 2020 - Despite a spate of therapeutic advances in recent years, neuroendocrine (NET) tumors remain a poorly investigated collection of cancers whose rarity has limited clinical trial enrollment. Now, genome sequencing studies are providing clues for ther...
Mar 29th, 2019 - Critique: Factors raising suspicion for Zollinger-Ellison syndrome include recurrent peptic ulcer disease, multiple ulcers, post-bulbar ulcer, non-H. pylori/non-NSAID-related duodenal ulcer, diarrhea, erosive esophagitis, and family or personal hi.
Lauren Bowen Tooker, PA-C, Kathy Dexter, MLS, MHA, MPA, PA-C
Jul 5th, 2017 - IN THIS ARTICLE Diagnostic criteria Pharmacologic management Patient education A more severe variant of peptic ulcer disease, Zollinger-Ellison syndrome (ZES) is a rare, chronic, and potentially life-threatening ulcerative disorder. Because the sy.